Compare LQDA & FBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LQDA | FBK |
|---|---|---|
| Founded | 2004 | 1906 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.8B |
| IPO Year | 2020 | 2016 |
| Metric | LQDA | FBK |
|---|---|---|
| Price | $37.97 | $53.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 4 |
| Target Price | $41.00 | ★ $64.50 |
| AVG Volume (30 Days) | ★ 1.0M | 282.3K |
| Earning Date | 05-08-2026 | 04-13-2026 |
| Dividend Yield | N/A | ★ 1.53% |
| EPS Growth | ★ 51.81 | N/A |
| EPS | N/A | ★ 2.45 |
| Revenue | ★ $158,320,000.00 | N/A |
| Revenue This Year | $278.87 | $41.72 |
| Revenue Next Year | $57.13 | $7.21 |
| P/E Ratio | ★ N/A | $22.38 |
| Revenue Growth | ★ 1031.18 | N/A |
| 52 Week Low | $11.85 | $42.21 |
| 52 Week High | $46.67 | $62.37 |
| Indicator | LQDA | FBK |
|---|---|---|
| Relative Strength Index (RSI) | 51.95 | 49.28 |
| Support Level | $35.00 | $52.27 |
| Resistance Level | $39.19 | $56.05 |
| Average True Range (ATR) | 1.94 | 1.41 |
| MACD | -0.21 | 0.00 |
| Stochastic Oscillator | 36.31 | 28.05 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
FB Financial Corp is a bank holding company. The company through its wholly-owned bank subsidiary provides commercial and consumer banking services to clients in select markets in Tennessee, North Alabama, and North Georgia. The company segment includes Banking and Mortgage. It generates majority of revenue from the Banking segment which provides a full range of deposit and lending products and services to corporate, commercial, and consumer customers. The Mortgage segment includes the servicing of residential mortgage loans and the packaging and securitization of loans to governmental agencies.